DrugFeb 8, 2023
Frenda Global Care 70% Alcohol Ethyl Rubbing Alcohol recall — FDA D-0260-2023
cGMP Deviations
Class IIFDA: TerminatedFrenda Corporation
Latest records
Latest recalls — page 323
The newest recall records with useful source details are listed here.
VehicleFeb 2, 2023
General Motors driveshaft recall — NHTSA campaign 23V043000
General Motors, LLC (GM) is recalling certain 2023 Cadillac XT5 and GMC Acadia vehicles. The right-front half-shaft assemblies may be improperly connected to the transmission, causing them…
driveshaftGeneral Motors, LLC
VehicleFeb 2, 2023
General Motors driveshaft recall — NHTSA campaign 23V042000
General Motors, LLC (GM) is recalling certain 2023 Chevrolet Blazer and Traverse vehicles. The left-side half-shaft assemblies may be missing a retaining ring.
driveshaftGeneral Motors, LLC
VehicleFeb 2, 2023
Honda display function recall — NHTSA campaign 23V046000
Honda (American Honda Motor Co.) is recalling certain 2018-2020 Fit and 2019-2022 HR-V vehicles. The rearview camera image may not display when the engine is started with a key, due to a…
display functionHonda (American Honda Motor Co.)
DrugFeb 1, 2023
Glaxosmithkline Consumer Healthcare Holdings DBA Advil (ibuprofen) Tablets, 200 mg, packaged recall — FDA D-0181-2023
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class IFDA: TerminatedGlaxosmithkline Consumer Healthcare Holdings DBA Haleon
DrugFeb 1, 2023
S2 Racepinephrine Inhalation Solution, USP 2.25% Bronchodilator 30x0.5 mL Sterile recall — FDA D-0176-2023
Short Fill
Class IIFDA: TerminatedNephron Sc Inc.
DrugFeb 1, 2023
Sterile Water for Injection, USP, For Drug Diluent Use Only, 5 mL Single-Dose Vial recall — FDA D-0178-2023
CGMP Deviations: potential for trace amounts of product carryover.
Class IIFDA: TerminatedNephron Sc Inc.
DrugFeb 1, 2023
Pharmacy Innovations MITOMYCIN 0.4MG/ML (1ML DROPTAINER) OPH SOLUTION recall — FDA D-0224-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Vancomycin Hydrochloride for Injection, USP, 1.5 g/vial, Sterile powder, Single-dose Fliptop recall — FDA D-0184-2023
Presence of Particulate Matter: Glass particulate matter detected in injectable.
Class IFDA: TerminatedPfizer Inc.
DrugFeb 1, 2023
Spectrum Laboratory Products Epinephrine (L-Adrenaline), USP, CAS 51-43-4 recall — FDA D-0180-2023
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
Class IFDA: TerminatedSpectrum Laboratory Products, Inc.
DrugFeb 1, 2023
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 100 mL Single-Dose Container bag recall — FDA D-0177-2023
CGMP Deviations: potential for trace amounts of product carryover.
Class IIFDA: TerminatedNephron Sc Inc.
DrugFeb 1, 2023
Pharmacy Innovations PROSTAGLANDIN (PE1) 45MCG (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 recall — FDA D-0234-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Glaxosmithkline Consumer Healthcare Holdings DBA Advil Liqui Gels, Solubilized ibuprofen recall — FDA D-0182-2023
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class IFDA: TerminatedGlaxosmithkline Consumer Healthcare Holdings DBA Haleon
DrugFeb 1, 2023
Pharmacy Innovations METHYLCOBALAMIN 12.5MG/ML (1ML VIAL) INJECTABLE METHYLCOBALAMIN 25MG/ML recall — FDA D-0222-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations Cyclosporine (A) 0.1% recall — FDA D-0200-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML recall — FDA D-0236-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Glaxosmithkline Consumer Healthcare Holdings DBA Advil Liqui Gels (minis), Solubilized recall — FDA D-0183-2023
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class IFDA: TerminatedGlaxosmithkline Consumer Healthcare Holdings DBA Haleon
DrugFeb 1, 2023
Pharmacy Innovations TESTOSTERONE 3% (4GM TUBE) OPHTH OINTME TESTOSTERONE CYP/ANASTROZOLE-GS recall — FDA D-0238-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations ESTRADIOL CYP/TEST CYP- SS OIL- 2MG/50MG/ML (1.5ML VIAL) INJECTABLE recall — FDA D-0206-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations PE1/PAPAV/ATROP/CHLOPROM** 7MCG/8.7MG/0.1MG/1.8MG/ML (1ML VIAL) recall — FDA D-0227-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations PAPAVERINE/PHENTOLAMINE 30MG/0.5MG/ML (1ML VIAL) INJECTABLE recall — FDA D-0226-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/HYDROXYCOBAL recall — FDA D-0239-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations GENTAMICIN BLADDER 0.08MG/ML (60ML SYRINGE) IRRIGATION recall — FDA D-0209-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Spectrum Laboratory Products Epinephrine (L-Adrenaline), USP, CAS 51-43-4, 1 KG amber glass recall — FDA D-0179-2023
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
Class IFDA: TerminatedSpectrum Laboratory Products, Inc.
Browse by month
Recent recall archives
Browse recent months with enough recall history for useful comparison.
August 2026149 records · 4 categoriesJuly 2026371 records · 4 categoriesJune 2026375 records · 4 categoriesMay 2026340 records · 4 categoriesApril 2026415 records · 4 categoriesMarch 2026190 records · 4 categoriesFebruary 2026331 records · 4 categoriesJanuary 2026212 records · 4 categoriesDecember 2025389 records · 4 categoriesNovember 2025326 records · 4 categoriesOctober 2025455 records · 4 categoriesSeptember 2025285 records · 4 categories